Allsup DJ et al. Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. Am J Hematol 2022;[Online ahead of print]. Abstract
Brown JR et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients. Haematologica 2021;[Online ahead of print]. Abstract
Byrd JC et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 2021;137(24):3327-38. Abstract
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Munir T et al. Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: Analysis from the phase III NCRI FLAIR trial. ASH 2021;Abstract 2636.
Seymour JF et al. Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 3721.
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Tang CPS et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol 2022;196(1):70-8. Abstract
Tedeschi A et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from arm D of the SEQUOIA (BGB-3111-304) trial. ASH 2021;Abstract 67.
Wierda WG et al. Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations. Leukemia 2021;35(11):3059-72. Abstract